Boehringer Ingelheim: Embryonic stem cells and animal models
January 2010. Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim evaluates prospects for animal models and stem cell technologies. What are corporate responsibilities specific for this area? What does the company expect from embryonic stem cells?Reading time: 3 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Bayer AG: New stakes in stem cells
Andreas Busch, Head of Global Drug Discovery on results, technology platforms, and expectations
Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan K. C. Knowles, at the time Head of Roche Group Research - open access
Novartis and Stem Cells
Mark Fishman, President Novartis Institutescomments on the company’s strategy and technology acquisitions in the field
Pfizer Embraces Regenerative Medicine
Ruth McKernan, CSO Pfizer Regenerative Medicine on the beginnings and competitors
Novo Nordisk - Commercialising Stem Cells
“Doing our business a little bit differently …”
Thinking Further About Stem Cells - Viewed from Systems Biology
Leroy Hood, President Institute for Systems Biology, Seattle, Washington (US)